Shared decision-making following disclosure of coronary heart disease genetic risk: Results from a randomized clinical trial

Hayan Jouni, Raad A. Haddad, Tariq S. Marroush, Sherry Ann Brown, Teresa M. Kruisselbrink, Erin E. Austin, Khader Shameer, Emma M. Behnken, Rajeev Chaudhry, Victor Manuel Montori, Iftikhar Jan Kullo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Whether disclosure of genetic risk for coronary heart disease (CHD) influences shared decision-making (SDM) regarding use of statins to reduce CHD risk is unknown. We randomized 207 patients, age 45-65†years, at intermediate CHD risk, and not on statins, to receive the 10-year risk of CHD based on conventional risk factors alone (n=103) or in combination with a genetic risk score (n=104). A genetic counselor disclosed this information followed by a physician visit for SDM regarding statin therapy. A novel decision aid was used in both encounters to disclose the CHD risk estimates and facilitate SDM regarding statin use. Patients reported their decision quality and physician visit satisfaction using validated surveys. There were no statistically significant differences between the two groups in the SDM score, satisfaction with the clinical encounter, perception of the quality of the discussion or of participation in decision-making and physician visit satisfaction scores. Quantitative analyses of a random subset of 80 video-recorded encounters using the OPTION5 scale also showed no significant difference in SDM between the two groups. Disclosure of CHD genetic risk using an electronic health record-linked decision aid did not adversely affect SDM or patients' satisfaction with the clinical encounter.

Original languageEnglish (US)
Pages (from-to)681-688
Number of pages8
JournalJournal of Investigative Medicine
Volume65
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Disclosure
Coronary Disease
Decision Making
Randomized Controlled Trials
Decision making
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Decision Support Techniques
Physicians
Electronic Health Records
Patient Satisfaction
Health

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Shared decision-making following disclosure of coronary heart disease genetic risk : Results from a randomized clinical trial. / Jouni, Hayan; Haddad, Raad A.; Marroush, Tariq S.; Brown, Sherry Ann; Kruisselbrink, Teresa M.; Austin, Erin E.; Shameer, Khader; Behnken, Emma M.; Chaudhry, Rajeev; Montori, Victor Manuel; Kullo, Iftikhar Jan.

In: Journal of Investigative Medicine, Vol. 65, No. 3, 01.03.2017, p. 681-688.

Research output: Contribution to journalArticle

Jouni, H, Haddad, RA, Marroush, TS, Brown, SA, Kruisselbrink, TM, Austin, EE, Shameer, K, Behnken, EM, Chaudhry, R, Montori, VM & Kullo, IJ 2017, 'Shared decision-making following disclosure of coronary heart disease genetic risk: Results from a randomized clinical trial', Journal of Investigative Medicine, vol. 65, no. 3, pp. 681-688. https://doi.org/10.1136/jim-2016-000318
Jouni, Hayan ; Haddad, Raad A. ; Marroush, Tariq S. ; Brown, Sherry Ann ; Kruisselbrink, Teresa M. ; Austin, Erin E. ; Shameer, Khader ; Behnken, Emma M. ; Chaudhry, Rajeev ; Montori, Victor Manuel ; Kullo, Iftikhar Jan. / Shared decision-making following disclosure of coronary heart disease genetic risk : Results from a randomized clinical trial. In: Journal of Investigative Medicine. 2017 ; Vol. 65, No. 3. pp. 681-688.
@article{8ce3f2c95fc1403e9dbbde2f72af0ad9,
title = "Shared decision-making following disclosure of coronary heart disease genetic risk: Results from a randomized clinical trial",
abstract = "Whether disclosure of genetic risk for coronary heart disease (CHD) influences shared decision-making (SDM) regarding use of statins to reduce CHD risk is unknown. We randomized 207 patients, age 45-65{\^a}€ years, at intermediate CHD risk, and not on statins, to receive the 10-year risk of CHD based on conventional risk factors alone (n=103) or in combination with a genetic risk score (n=104). A genetic counselor disclosed this information followed by a physician visit for SDM regarding statin therapy. A novel decision aid was used in both encounters to disclose the CHD risk estimates and facilitate SDM regarding statin use. Patients reported their decision quality and physician visit satisfaction using validated surveys. There were no statistically significant differences between the two groups in the SDM score, satisfaction with the clinical encounter, perception of the quality of the discussion or of participation in decision-making and physician visit satisfaction scores. Quantitative analyses of a random subset of 80 video-recorded encounters using the OPTION5 scale also showed no significant difference in SDM between the two groups. Disclosure of CHD genetic risk using an electronic health record-linked decision aid did not adversely affect SDM or patients' satisfaction with the clinical encounter.",
author = "Hayan Jouni and Haddad, {Raad A.} and Marroush, {Tariq S.} and Brown, {Sherry Ann} and Kruisselbrink, {Teresa M.} and Austin, {Erin E.} and Khader Shameer and Behnken, {Emma M.} and Rajeev Chaudhry and Montori, {Victor Manuel} and Kullo, {Iftikhar Jan}",
year = "2017",
month = "3",
day = "1",
doi = "10.1136/jim-2016-000318",
language = "English (US)",
volume = "65",
pages = "681--688",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Shared decision-making following disclosure of coronary heart disease genetic risk

T2 - Results from a randomized clinical trial

AU - Jouni, Hayan

AU - Haddad, Raad A.

AU - Marroush, Tariq S.

AU - Brown, Sherry Ann

AU - Kruisselbrink, Teresa M.

AU - Austin, Erin E.

AU - Shameer, Khader

AU - Behnken, Emma M.

AU - Chaudhry, Rajeev

AU - Montori, Victor Manuel

AU - Kullo, Iftikhar Jan

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Whether disclosure of genetic risk for coronary heart disease (CHD) influences shared decision-making (SDM) regarding use of statins to reduce CHD risk is unknown. We randomized 207 patients, age 45-65†years, at intermediate CHD risk, and not on statins, to receive the 10-year risk of CHD based on conventional risk factors alone (n=103) or in combination with a genetic risk score (n=104). A genetic counselor disclosed this information followed by a physician visit for SDM regarding statin therapy. A novel decision aid was used in both encounters to disclose the CHD risk estimates and facilitate SDM regarding statin use. Patients reported their decision quality and physician visit satisfaction using validated surveys. There were no statistically significant differences between the two groups in the SDM score, satisfaction with the clinical encounter, perception of the quality of the discussion or of participation in decision-making and physician visit satisfaction scores. Quantitative analyses of a random subset of 80 video-recorded encounters using the OPTION5 scale also showed no significant difference in SDM between the two groups. Disclosure of CHD genetic risk using an electronic health record-linked decision aid did not adversely affect SDM or patients' satisfaction with the clinical encounter.

AB - Whether disclosure of genetic risk for coronary heart disease (CHD) influences shared decision-making (SDM) regarding use of statins to reduce CHD risk is unknown. We randomized 207 patients, age 45-65†years, at intermediate CHD risk, and not on statins, to receive the 10-year risk of CHD based on conventional risk factors alone (n=103) or in combination with a genetic risk score (n=104). A genetic counselor disclosed this information followed by a physician visit for SDM regarding statin therapy. A novel decision aid was used in both encounters to disclose the CHD risk estimates and facilitate SDM regarding statin use. Patients reported their decision quality and physician visit satisfaction using validated surveys. There were no statistically significant differences between the two groups in the SDM score, satisfaction with the clinical encounter, perception of the quality of the discussion or of participation in decision-making and physician visit satisfaction scores. Quantitative analyses of a random subset of 80 video-recorded encounters using the OPTION5 scale also showed no significant difference in SDM between the two groups. Disclosure of CHD genetic risk using an electronic health record-linked decision aid did not adversely affect SDM or patients' satisfaction with the clinical encounter.

UR - http://www.scopus.com/inward/record.url?scp=85014603931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014603931&partnerID=8YFLogxK

U2 - 10.1136/jim-2016-000318

DO - 10.1136/jim-2016-000318

M3 - Article

C2 - 27993947

AN - SCOPUS:85014603931

VL - 65

SP - 681

EP - 688

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 3

ER -